EU firms want up to two years to comply with black symbol rule for monitored drugs
This article was originally published in SRA
Executive Summary
Pharmaceutical companies and other stakeholders have told the European Commission that they will require a realistic transitional period, possibly up to two years, to fully implement the new requirement for a black symbol to be printed on the product information of medicines subject to additional monitoring1-3. They have also urged the commission to ensure that there is no need to recover or destroy stocks of products or packaging already in the supply chain.